Shares of PLx Pharma Inc (NASDAQ:PLXP) have received a consensus broker rating score of 2.00 (Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy rating.

Analysts have set a 1 year consensus price target of $12.00 for the company, according to Zacks. Zacks has also assigned PLx Pharma an industry rank of 108 out of 265 based on the ratings given to related companies.

PLXP has been the subject of several research analyst reports. ValuEngine raised PLx Pharma from a “strong sell” rating to a “sell” rating in a research note on Monday, December 4th. Zacks Investment Research raised PLx Pharma from a “sell” rating to a “hold” rating in a research report on Thursday, October 12th.

PLx Pharma (NASDAQ:PLXP) opened at $6.65 on Friday. PLx Pharma has a one year low of $5.60 and a one year high of $22.00. The company has a quick ratio of 8.88, a current ratio of 8.99 and a debt-to-equity ratio of 0.56.

An institutional investor recently bought a new position in PLx Pharma stock. Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of PLx Pharma Inc (NASDAQ:PLXP) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 250,000 shares of the biotechnology company’s stock, valued at approximately $145,000. Harel Insurance Investments & Financial Services Ltd. owned approximately 2.88% of PLx Pharma as of its most recent filing with the Securities and Exchange Commission (SEC). 21.87% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “PLx Pharma Inc (PLXP) Receives Average Recommendation of “Buy” from Analysts” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/12/17/plx-pharma-inc-plxp-receives-average-recommendation-of-buy-from-analysts.html.

PLx Pharma Company Profile

PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.

Get a free copy of the Zacks research report on PLx Pharma (PLXP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.